143 related articles for article (PubMed ID: 38299565)
1. A virtual insight into mushroom secondary metabolites: 3D-QSAR, docking, pharmacophore-based analysis and molecular modeling to analyze their anti-breast cancer potential.
Shafiq N; Shakoor B; Yaqoob N; Parveen S; Brogi S; Mohammad Salamatullah A; Rashid M; Bourhia M
J Biomol Struct Dyn; 2024 Feb; ():1-22. PubMed ID: 38299565
[TBL] [Abstract][Full Text] [Related]
2. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
4. Exploring
Zia M; Parveen S; Shafiq N; Rashid M; Farooq A; Dauelbait M; Shahab M; Salamatullah AM; Brogi S; Bourhia M
ACS Omega; 2024 Jan; 9(2):2161-2182. PubMed ID: 38250382
[TBL] [Abstract][Full Text] [Related]
5. Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors.
Huang L; Wu X; Fu X; Wang H; Tang B; Xiao Y; Zhou C; Zhao Z; Wan Y; Chen H; Tang Z; Yao H; Shan Z; Bu T
J Biomol Struct Dyn; 2022 Oct; 40(16):7584-7597. PubMed ID: 33734039
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking, QSAR, pharmacophore modeling, and dynamics studies of some chromone derivatives for the discovery of anti-breast cancer agents against hormone-dependent breast cancer.
Arvindekar SA; Mohole S; Patil A; Mane P; Arvindekar A; Mali SN; Thorat B; Rawat R; Sharma S
J Biomol Struct Dyn; 2023; 41(24):14757-14770. PubMed ID: 36995997
[TBL] [Abstract][Full Text] [Related]
7. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
Zaka M; Abbasi BH; Durdagi S
J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
[TBL] [Abstract][Full Text] [Related]
9. Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Aug; 37(12):3150-3161. PubMed ID: 30114965
[TBL] [Abstract][Full Text] [Related]
10. In silico studies on potential MCF-7 inhibitors: a combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis.
Badhani B; Kakkar R
J Biomol Struct Dyn; 2017 Jul; 35(9):1950-1967. PubMed ID: 27401212
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches.
Lanka G; Banerjee S; Adhikari N; Ghosh B
Mol Divers; 2024 Apr; ():. PubMed ID: 38637479
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic QSAR modeling derived virtual screening, drug repurposing, ADMET and
Jawarkar RD; Zaki MEA; Al-Hussain SA; Al-Mutairi AA; Samad A; Masand V; Humane V; Mali S; Alzahrani AYA; Rashid S; Elossaily GM
J Biomol Struct Dyn; 2024 Feb; ():1-31. PubMed ID: 38385447
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
[TBL] [Abstract][Full Text] [Related]
14. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
Islam MR; Osman OI; Hassan WMI
J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
Shah BM; Modi P; Trivedi P
J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496
[TBL] [Abstract][Full Text] [Related]
16.
Akabli T; Toufik H; Lamchouri F
J Biomol Struct Dyn; 2022 Jun; 40(9):3965-3978. PubMed ID: 33252029
[TBL] [Abstract][Full Text] [Related]
17. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
[TBL] [Abstract][Full Text] [Related]
18. Identifying natural products for gastric cancer treatment through pharmacophore creation, 3D QSAR, virtual screening, and molecular dynamics studies.
Jalali Z; Nejad Ebrahimi S; Rezadoost H
Daru; 2023 Dec; 31(2):243-258. PubMed ID: 37733194
[TBL] [Abstract][Full Text] [Related]
19. Identification of 1,3,4-oxadiazoles as tubulin-targeted anticancer agents: a combined field-based 3D-QSAR, pharmacophore model-based virtual screening, molecular docking, molecular dynamics simulation, and density functional theory calculation approach.
Das A; Sarangi M; Jangid K; Kumar V; Kumar A; Singh PP; Kaur K; Kumar V; Chakraborty S; Jaitak V
J Biomol Struct Dyn; 2023 Sep; ():1-19. PubMed ID: 37695635
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
